| Vol. 6.30 – 19 August, 2022 |
| |
|
|
| The authors found that the occurrence of vessel co-option in bevacizumab-resistant colorectal cancer liver metastasis xenografts was associated with increased expression of fibroblast activation protein alpha in the co-opted hepatic stellate cells. [Journal of Clinical Investigation] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers employed nanopillar arrays to guide subnuclear features into ordered patterns, enabling their quantification as a strong indicator of cell malignancy. [Nano Letters] |
|
|
|
| Scientists showed that hepatocytes accumulated centrioles during cycles of polyploidization in vivo. [Genes & Development] |
|
|
|
| Investigators demonstrated that Arid1a knockout may have resulted in states of different cell differentiation, as indicated by single-cell RNA sequencing analysis. [Cancer Letters] |
|
|
|
| Preventing ferroptotic cell death in hepatocytes by deleting Acsl4 did not increase the formation of HCC. Furthermore, Acsl4-deficient livers displayed less fibrosis and proliferation, especially in an HCC model of toxic damage. [Cell Death & Disease] |
|
|
|
| The authors used FOXA2 mutant induced pluripotent stem cell (iPSC) lines to understand the role of FOXA2 on the development and function of human hepatocytes. [Cell Death & Disease] |
|
|
|
| Investigators demonstrated that hepatocytes were susceptible to infection in different models: primary hepatocytes derived from humanized angiotensin-converting enzyme-2 mice and primary human hepatocytes. [Communications Biology] |
|
|
|
| Scientists identified a novel candidate oncogene, RPL22L1, which was markedly elevated in HCC and contributed to HCC malignancy and adverse patient survival. [Cell Death Discovery] |
|
|
|
| Researchers used in vitro models of HBV-infected cells, based on both primary human hepatocytes and the non-transformed HepaRG cell line to investigate the MoA of Pam3SCK4 and identify relevant combinations with other approved or investigational drugs. [Antiviral Research] |
|
|
|
| Approaches were developed for gene delivery through viral transduction of human hepatocytes either in vivo, or in vitro prior to engraftment, providing a novel platform to study liver disease and hepatocyte-targeted therapies. [Scientific Reports] |
|
|
|
| Investigators used both in vivo and in vitro assays to assess the effect and mechanisms of salidroside on hepatic ischemia-reperfusion injury. [Scientific Reports] |
|
|
|
| Researchers reported the perfusion culture of a multi-layered tissue composed of HepG2 cells in a pressure-driven microphysiological system, which they developed previously as a multi-throughput perfusion culture platform. [Journal of Bioscience and Bioengineering] |
|
|
|
|
|
| The authors discuss recent developments in etiology and prospective therapeutic targets, as well as pharmacological candidates in pre-clinical trials and patents, with a focus on diabetes, hepatic lipid metabolism, inflammation, and fibrosis. [Signal Transduction and Targeted Therapy] |
|
|
|
| Scientists highlight the emerging roles of lincRNA-p21 in cancer cell regulation. Various types of cancers, including colorectal carcinoma, HCC, and non-small cell lung carcinoma aberrantly express lincRNA-p21. [Human Cell] |
|
|
|
|
| 89bio, Inc. announced that it has completed enrollment in ENLIVEN, the Phase IIb trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH). [89bio, Inc.] |
|
|
|
|
| November 13 – 18, 2022 Ventura, California, United States |
|
|
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| University of Kansas Medical Center – Kansas City, Kansas, United States |
|
|
|
| Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| Mayo Clinic – Scottsdale, Arizona, United States |
|
|
|
|